Cyclacel Pharmaceuticals (CYCC) Environmental, Social & Governance (ESG) Data

Company Profile

Search within these filings

View filings

Exhibits within filings

Filing insights

Export filings list

Export a CSV file of filings or unique filing companies (up to first 5,000 results).

Download list of filings Download list of companies

Employees

Data from SEC filings

Employee count

ESG framework mentions

In last year of SEC filings

Sustainability Accounting Standards Board (SASB)

No mentions

Global Reporting Initiative (GRI)

No mentions

Task Force on Climate-related Financial Disclosures (TCFD)

No mentions

UN Sustainable Development Goals (SDGs)

No mentions

ESG term mentions

In last year of SEC filings

Carbon Footprint Environment Environmental Escape Hazard Intensity Materials Natural Resources Nature Ocean Offset Package Packaging Pandemic Raw Materials Toxic Waste Access Affordability Benefits Black California Consumer Privacy Act Charitable Citizenship Community Culture Customer Cyber Data Privacy Data Security Death Demographic Disability Diversity Diversity and Inclusion Drug Pricing Employee Engagement Ethnicity Gender General Data Protection Regulation Health Care Healthcare Hire Hiring Human Capital Incident Injured Injury Overtime Pay for Performance Privacy Recall Recruit Recruitment Reimbursement Retention Retirement Safety Satisfaction Skilled Skills Social Society Stakeholder Supplier Supply Chain Talent Training Union Volunteer Women Workers Workforce Action Plan Assessment Assurance Attorney General Audit Bonus Chronic Class Action Lawsuit Classified Clawback Commitment Conflict of Interest Corporate Governance Department of ESG Ethics Executive Compensation Expert Fraud Goals Hedging Incentive Independence Independent Innovation Innovative Investigation Lawsuit Leadership Litigation Long-term Majority Materiality Mission Oversee Oversight Proxy Contest Purpose Quality Standard R&D Reputation Reputational Research and Development Responsibility Responsible Special Meeting Strategy Sustainable Targets Tax Tenure Transparency Voting Rights

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

The actions set forth below were taken at the Annual Meeting.

Proposals Submitted to Holders of Common Stock

The following proposals were submitted to the holders of the Company’s shares of common stock and voted upon at the Annual Meeting: (i) the re-election of two Class 1 directors to the Company’s board of directors, (ii) the ratification of the selection of RSM US LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2022, (iii) the approval of an amendment to the Company’s 2018 Equity Incentive Plan, and (iv) the approval, on an advisory basis, of the executive compensation of the Company’s named executive officers, as disclosed in the Company’s proxy statement.

(i) Votes of the common stockholders regarding the election of the Class 1 director nominees were as follows:

			Votes For				Votes Withheld				Broker Non-Votes
Dr. Samuel L. Barker			2,604,913				266,432				3,560,063
Karin L. Walker			2,639,846				231,499				3,560,063

Based on the votes set forth above, Dr. Samuel L. Barker and Karin L. Walker were duly re-elected as Class 1 directors of the Company to serve until the 2025 annual meeting of stockholders or until their respective successors are elected and qualified or until their earlier resignation or removal.

(ii) Votes of the common stockholders regarding the ratification of RSM US LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2022 were as follows:

Votes For		Votes Against		Abstentions		Broker Non-Votes
5,909,971		408,936		112,501		0

Based on the votes set forth above, the selection of RSM US LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2022 was ratified.

(iii) Votes of the common stockholders regarding the approval of an amendment to the Company’s 2018 Equity Incentive Plan were as follows:

Votes For		Votes Against		Abstentions		Broker Non-Votes
2,365,534		403,836		101,975		3,560,063

Based on the votes set forth above, the proposal to approve an amendment to the Company’s 2018 Equity Incentive Plan was approved.

(iv) Votes of the common stockholders, on an advisory basis, regarding the executive compensation of the Company’s named executive officers, as disclosed in the Company’s proxy statement, were as follows:

Votes For		Votes Against		Abstentions		Broker Non-Votes
2,456,357		394,675		20,313		3,560,063

Based on the votes set forth above, the proposal to approve the executive compensation of the Company’s named executive officers, as disclosed in the Company’s proxy statement, was approved on an advisory basis.

Proposals Submitted to Holders of Preferred Stock

The election of Dr. Kenneth M. Ferguson as a Class 1 director to the Company’s board of directors was submitted to the holders of the Company’s shares of 6% Convertible Exchangeable Preferred Stock (the “Preferred Stock”) and voted upon at the Annual Meeting. Votes of the preferred stockholders regarding the election of Dr. Kenneth M. Ferguson as a Class 1 director were as follows:

		Votes For				Votes Against				Abstentions				Broker Non-Votes
Dr. Kenneth M. Ferguson			226,160				3,310				6,966				0

Based on the votes set forth above, Dr. Kenneth M. Ferguson was duly elected as a Class 1 director of the Company to serve until the 2025 annual meeting of stockholders or until his respective successor is elected and qualified or until his earlier resignation or removal.